Intercalating Erlotinib with Platinum Chemotherapy Prolongs Survival in NSCLC
Intercalating erlotinib with platinum-based chemotherapy prolongs progression-free survival (PFS) in first-line advanced non-small cell lung cancer (NSCLC).
ASCO 2012
Drug Shortages Lead to Substantial Increase in Costs; Mandate Treatment Changes
Shortages in oncology drugs “increased at an alarming rate” in just one year.
ASCO: Regorafenib Prolongs PFS and DCS in Patients with Advanced Metastatic or Unresectable GIST
Regorafenib significantly prolongs progression-free survival (PFS) and disease control rate (DCS) among patients with advanced metastatic or unresectable gastrointestinal stromal tumor (GIST).
Carfilzomib Effective, Tolerated as Replacement for Bortezomib in Multiple Myeloma
Carfilzomib is an effective and tolerable replacement for bortezomib for patients who are refractory to bortezomib-containing combination regimens for the treatment of multiple myeloma.
No Efficacy Increase Found for Pemetrexed-Cetuximab Combination in NSCLC
Adding cetuximab to regimens containing pemetrexed does not improve survival rates in patients with recurrent or progressive non-small cell lung cancer (NSCLC) after platinum-based therapy.
No Significant Improvement Seen When Everolimus Added to First-Line Paclitaxel/Bevacizumab in HER2-Negative Metastatic Breast Cancer
Adding everolimus (Afinitor) did not significantly improve the efficacy of weekly paclitaxel/bevacizumab in the first-line treatment of HER2-negative metastatic breast cancer.
Dr. Sergio A. Giralt Offers Commentary on Hematologic Oncology Coverage at ASCO 2012
Initial salvage treatment with allogenic stem cell transplant (ASCT) is feasible and yields superior outcomes to salvage chemotherapy in acute myeloid leukemia (AML) patients.
High Complete Remission Rate for Blinatumomab in Relapsed/Refractory B-Precursor ALL
Adult patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL) treated with blinatumomab had a 72% response rate.
ASCO: Afatinib Prolongs PFS among EGFR-Mutation-Positive Lung Cancer Patients
Afatinib significantly prolongs progression-free survival (PFS) among EGFR-mutation-positive lung cancer, compared to pemetrexed plus cisplatin.
First-line Lapatinib/Taxane Inferior to Trastuzumab/Taxane in HER2+ Metastatic Breast Cancer
Taxane-based chemotherapy plus lapatinib is associated with a shorter progression-free survival (PFS) than when combined with trastuzumab as first-line treatment for patients with HER2+ metastatic breast cancer.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Loading... 
Loading...